FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely…
Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for…
Read More...
Read More...